Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
about
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsDiagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyUpdates on the risk factors for latent tuberculosis reactivation and their managementsGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveScaling up programmatic management of drug-resistant tuberculosis: a prioritized research agendaVariations of care quality for infectious pulmonary tuberculosis in Taiwan: a population based cohort study.U.S. medical resident familiarity with national tuberculosis guidelinesEligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature reviewPredictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort studyNew approaches in the diagnosis and treatment of latent tuberculosis infectionHigh-resolution melting curve analysis for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Current concepts in the management of tuberculosisThe use of anti-tuberculosis therapy for latent TB infectionClose contact investigation of TB in high-burden, low- and middle-income countries.Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.Current development and future prospects in chemotherapy of tuberculosisRifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.Occupational deaths among healthcare workersIsoniazid preventive therapy and risk for resistant tuberculosis.Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.Liver Transplantation in Antituberculosis Drugs-Induced Fulminant Hepatic Failure: A Case Report and Review of the Literature.Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.Latent tuberculosis: revised treatment guidelines.A Case of Presumed Tuberculosis Uveitis with Occlusive Vasculitis from an Endemic Region.Management of Latent Tuberculosis Infection among Healthcare Workers: 10-year Experience at a Single Center.Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.Needed: new and better tools to combat latent tuberculosis infection.Rapid Detection of Streptomycin-Resistant Mycobacterium tuberculosis by rpsL-Restriction Fragment Length Polymorphism.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysisImpact of immunopathology on the antituberculous activity of pyrazinamide
P2860
Q24650581-355C992E-0E81-4922-948C-57B67235376AQ27005716-2C9CF817-C07C-4A3F-9A05-CC4A2B663CABQ28073158-7A804ADC-2095-4C1A-8DEE-A46976C16A40Q28388806-CB67273D-FEAF-434D-A7A6-07F842CEFDCEQ28473126-91C76C06-671D-4313-9A5F-D5A8ED970E29Q33287351-90F7D3CB-4371-4CD9-8322-0480A99FAF0DQ33293231-8665D51C-8908-4E6B-9FD3-F94F95555BFEQ33692355-EC7DE8CD-807E-43D9-9192-119F43CEE03CQ33882852-E9694325-A28E-428E-97D3-87A7428B7DB2Q34116293-A7E4B036-A39F-4275-ADF7-C846428F3057Q34312746-287865BF-6484-4269-878B-8694D15AB507Q34419185-70965D02-6829-4512-A996-B335DE2C382BQ34489647-BA8C93C4-A461-4A52-8473-BC0C838226EEQ34737143-1633C9AB-9658-48AA-85CA-C07CF03F1E58Q34748542-2F7E3CB1-2F9B-4D02-BBA2-FE45AD9723C9Q35026573-1E8EF0D0-8ECB-43C5-B6F5-6E26FBB871ADQ35443130-BABBC260-5D3B-45B9-9752-15879C71F658Q35607718-D7383A33-EE31-4998-B711-F2A29C6EAF76Q35705874-938D1881-64D0-4A69-95AB-CD58DDBE00C5Q35754209-37222FB9-06A8-49B3-AC66-67AC68BB4B18Q36019231-8494FC13-6FB5-4158-9096-CEF204D7D315Q36021941-62A4EEAB-BA1C-467D-AB1C-0B30483C880DQ36029457-6C926400-9DC7-4D85-B7C7-35B84EA27ED2Q36042709-90E1AA1C-FC0D-488F-8486-73450CDB3266Q37221167-46EDD1E4-EDB2-4BFF-9A97-C327B8F75974Q37225859-6F444002-38B2-4DCF-A3C2-D48F4649F5B8Q37443290-0B18B2F0-D342-4EEB-B2EC-71B612AAF5D8Q37613267-29EA8090-205B-4E44-8630-2EF7CBD18271Q39982606-4CD811FB-6008-4403-B32D-065A27E6883EQ40051918-1E9C4A12-383A-4165-B815-CB98252FFD8EQ41987069-FCC2B8D2-86BE-4F9C-9A22-C2BDA605DFEFQ42111332-F719A941-3A91-48A0-BD41-6320014BE57DQ42859871-8FCD41E2-4B3E-45A5-84E6-ADAF2346F57AQ44387076-18A424A6-8DC8-4D9A-86C8-D81B61C60617Q49508046-145B2729-B5EE-4598-9499-D7DC370C4BE2Q54220210-C411BAD1-15C1-495B-820B-84BD278B8C53Q57568082-5BF9C53F-C7B8-427E-A999-E8065E5590A0Q58799356-B19832EE-DDF7-4839-8F20-C5A1A9D0474F
P2860
Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Update: adverse event data and ...... nfection--United States, 2003.
@ast
Update: adverse event data and ...... nfection--United States, 2003.
@en
type
label
Update: adverse event data and ...... nfection--United States, 2003.
@ast
Update: adverse event data and ...... nfection--United States, 2003.
@en
prefLabel
Update: adverse event data and ...... nfection--United States, 2003.
@ast
Update: adverse event data and ...... nfection--United States, 2003.
@en
P1476
Update: adverse event data and ...... nfection--United States, 2003.
@en
P304
P577
2003-08-01T00:00:00Z